Tag Archives: VTGN

Top 10 Bank Stocks To Invest In Right Now

 Today, I (Porter) am going to introduce a new financial term…   I've been thinking about this a while… it's a term that describes the modern economy's fondness for central banks, paper money, huge debts, and financial bubbles. I call it the "Escher Economy."   I hope you'll read carefully. Remember… there's no such thing as teaching, only learning.    About five years ago, investors around the world began piling into Japanese stocks…   It was a surprising move.   Japanese stocks have been a virtual graveyard for capital since the late 1980s. That's when Japan's big real estate and investment bubble collapsed. The Japanese "Dow" – the Nikkei 225 Index – briefly soared from around 10,000 to more than 40,000… and then collapsed.

Top 10 Bank Stocks To Invest In Right Now: Monotype Imaging Holdings Inc.(TYPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Monotype Imaging Holdings Inc. (NASDAQ: TYPE) were down around 12 percent to $20.90 after the company posted downbeat quarterly earnings.

  • [By Lisa Levin]

    Wednesday afternoon, the non-cyclical consumer goods & services shares surged 0.61 percent. Meanwhile, top gainers in the sector included Monotype Imaging Holdings Inc. (NASDAQ: TYPE), up 9 percent, and Semiconductor Manufacturing Int'l (ADR) (NYSE: SMI), up 6 percent.

Top 10 Bank Stocks To Invest In Right Now: CBOE Holdings Inc.(CBOE)

Advisors’ Opinion:

  • [By David Zeiler]

    Bats Global Markets was acquired on Feb. 28 by the Chicago Board Options Exchange (Nasdaq: CBOE).

    But the Bats BZX Exchange has had a bigger role than just serving as the place where the Winklevoss ETF will be listed…

  • [By David Zeiler]

    Bitcoin futures trading started at the CBOE Global Markets Inc. (Nasdaq: CBOE) on Dec. 10 and on the much larger CME Group Inc. (Nasdaq: CME) on Dec. 18. Nasdaq Inc. (Nasdaq: NDAQ) plans to begin trading Bitcoin futures in the first half of next year.

  • [By CNNMoney Staff]

    Stocks continued to rally despite the fact that options trading was temporarily halted Monday afternoon at exchanges run by CBOE Holdings (CBOE), Nasdaq OMX (NDAQ), BATS Global Markets and Miami International Holdings due to issues at the Options Price Reporting Authority (OPRA), which provides trading data and price quotes.

  • [By Wayne Duggan]

    Wall Street has been watching bitcoin this week, with the price up another 39.8 percent to above $16,000 ahead of the highly anticipated launch of bitcoin futures trading by Cboe Global Markets Inc (NASDAQ: CBOE) starting Sunday. Bitcoin has been around for years, but bitcoin futures trading will make trading a breeze for average retail investors for the first time.

  • [By Saumya Vaishampayan
    var popups = $(“.socialByline .popC”); ]

    Those who dabble in derivatives tied to the CBOE (CBOE) Volatility Index are placing bets that pay out if the stock market keeps swinging, and especially if it drops.

Top 10 Bank Stocks To Invest In Right Now: Forward Pharma A/S(FWP)

Advisors’ Opinion:

  • [By Jim Robertson]

    Last Friday, our Under the Radar Moversnewsletter suggested going long on small cap clinical-stage biopharmaceutical stock Forward Pharma A/S (NASDAQ: FWP):

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

Top 10 Bank Stocks To Invest In Right Now: Internet Gold Golden Lines Ltd.(IGLD)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, telecommunications services shares fell by 0.43 percent. Meanwhile, top losers in the sector included Internet Gold Golden Lines Ltd (NASDAQ: IGLD), down 10 percent, and China Unicom (Hong Kong) Limited (ADR) (NYSE: CHU), down 3 percent.

Top 10 Bank Stocks To Invest In Right Now: Lam Research Corporation(LRCX)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wednesday was a mixed day for the stock market, as the Dow Jones Industrials dropped by triple digits but other major benchmarks fared much better. Crude oil prices fell nearly $2 per barrel to $50.50, and that hurt energy companies, along with a poor earnings report from technology giant IBM. Yet the broader market held up better, and the Nasdaq Composite actually gained ground. In particular, some good news from a few individual companies helped hold the markets up, and CalAmp (NASDAQ:CAMP), Lithia Motors (NYSE:LAD), and Lam Research (NASDAQ:LRCX) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By WWW.THESTREET.COM]

    The same case is made for Action Alerts PLUS holding Alphabet (GOOGL) and for Lam Research (LRCX) and Broadcom (AVGO) and Growth Seeker holding Amazon (AMZN) –and a host of other high-growth companies.

  • [By Ben Levisohn]

    Lam Research (LRCX) soared to the top of the S&P 500 today after beating earnings forecasts and raising its fourth-quarter guidance.

    Getty Images

    Lam Researchgained 6.9% to $136.17 today, while the S&P 500 declined 0.2% to 2,338.17.

    Credit Suisse analysts Farhan Ahmad and John Pitzer and argues that Lam Research’s “new trough is higher than [its] old peak.” They explain:

    We expect that bears will continue to argue that CY17 is a “Peak” year; however we think that investors are missing that it now costs >2x more to get incremental bit growth than three years ago. It is noteworthy that despite ~$17bn of memory WFE in 2016 both NAND and DRAM markets went from oversupply to undersupply – implying that new trough for memory investments is even higher than old peak (2010 memory peak had WFE of $12.6bn). We view Semi Growth, rising capital intensity, and growing China CapEx as secular multiyear themes, which could continue to provide growth in coming years. In addition, in case of tax reform there could be potential to return >$50 per share to shareholders by 2020…Increase TP to $160 (from $143), based on 12x of CY18 EPS plus net cash adj for taxes.

    Lam Research’s market capitalization rose to $22.2 billion today from $20.8 billion yesterday.

  • [By WWW.MONEYSHOW.COM]

    Lam Research (LRCX) has consistently outgrown the overall semiconductor-equipment market due to its high exposure to 3D NAND flash memory.

    Demand for wafer-fabrication equipment is notoriously volatile. However, over the last 90 days, the consensus profit estimate for this year jumped 17%, with 95% of analysts raising their targets.

Top 10 Bank Stocks To Invest In Right Now: VistaGen Therapeutics, Inc. (VTGN)

Advisors’ Opinion:

  • [By Money Morning News Team]

    For instance, VistaGen Therapeutics Inc. (Nasdaq: VTGN) shot up from $0.92 to $2.55 on Dec. 6. Since then, the stock pulled back to $1.02. Investors who bought at $2.55 are sitting on a 60% loss today (Dec. 18).

  • [By William Romov]

    VistaGen Therapeutics Inc. (Nasdaq: VTGN) is among the top penny stocks to watch this week after climbing 135% in just three trading sessions last week.

  • [By SEEKINGALPHA.COM]

    Four ideas turned up in this screen that might be of interest (prices as of February 9th close):

    Heron Therapeutics (NASDAQ:HRTX) by ONeil Trader – published February 3rd, 2017, $525M Market cap, down ~2% since publication, author’s price target offers 130% upside. HRTX isn’t a generic drug provider, but its CINV franchise vs. the growth of a new drug gives it a similar sort of profile, and arguably a favorable risk/reward; commenters were mostly positive on the thesis. VistaGen Therapeutics (OTC:VTGN) by Logical Assessment – published July 29, 2016, $24M market cap, down 16% since publication, author’s price target offers 100%+ upside. This is obviously deeper into the speculative pile, but if the author’s thesis holds about VistaGen’s unique angle in the antidepressant drug space, comparable deals suggest good upside. (Of course, it’s always dangerous to rely solely on comparables). Dr. Reddy’s Laboratories (NYSE:RDY) by Buddy Lyons – published July 5, 2016, $7.6B market cap, down ~13% since publication, author’s price target offers just shy of 100% upside. Dr. Reddy’s is a more obvious comparable to TEVA, with a generics business but also a manufacturing business and a proprietary products branch. The company bought a divestiture package of drugs from TEVA as part of the Allergan/Actavis deal. A big overhang was an FDA warning letter; the FDA is due to reinspect facilities this month or next, which could resolve that one way or another. Lannett (NYSEMKT:LCI) by Lateral Capital Management – published May 27, 2016, $750M market cap, down ~9% since publication, author’s price target offers 75% upside. LCI’s trading had been 90% correlated with Valeant, but Lateral Capital Management argues that the correlation is unjustified. The article does a deep dive into the company’s valuation and credit risk, and was well received at the time, even if the market hasn’t agreed…yet.

    I also checked to see if there are any ideas starting to play out on the short si

Top 10 Bank Stocks To Invest In Right Now: Grow Solutions Holdings, Inc. (GRSO)

Advisors’ Opinion:

  • [By Javier Hasse]

    Grow Solutions Holdings Inc (OTC: GRSO) acquired Keys Organic and Hydroponic Supply.

    "What we are starting to see here is aggregation in the highly-fragmented hydroponic and grow supply industry. Most of these stores, including Keys Organic and Hydroponic Supply, are typically local or regional — This results in a very fragmented market."
    "We saw this [aggregation] happen with grocery stores, the finance industry, auto dealerships — Bigger names come in. So, instead of Bob's Ford Motor Company (NYSE: F) Dealership or Fred'sGeneral Motors Company (NYSE: GM) outlet, you'll get companies likeAutoNation, Inc. (NYSE: AN) come in, put them under a single brand, consolidate HR and other expenses to develop economies of scale and really help additional bottom line."
    “Another way to look at it is, there's coffee shops all around the world, but there's also Starbucks Corporation (NASDAQ: SBUX), which started locally […] and developed really organically. But, they could just buy the local coffee shop, redesign it to the Starbucks brand, put their name on it… Now they have the distribution network, the backing of Starbucks, Starbucks will take care of their HR, their payroll — It's a more synergistic approach and a really value-add if they can consolidate any level of scale.”

    Elev8 Brands Inc (OTC: VATE) acquired O2 Breathe, LLC, a company supplying portable oxygen bars and aromatherapy inhalers.

Top 10 Bank Stocks To Invest In Right Now: Atkore International Group Inc. (ATKR)

Advisors’ Opinion:

  • [By Spencer Israel]

    3. Atkor International Group Inc (NYSE: ATKR) – Five of the six analyst ratings on the manufacturing holding company have been bullish. With the stock showing very strong technical support at $16, and currently trading at $16.68, Stockal's confidence meter is at 90%. 

  • [By Ben Levisohn]

    Flexing the barbell strategy to balance Safe Havens with more cyclical exposures. In our view, industrials investors should be positioning their portfolio with a barbell strategy, with half of the exposure in Safe Havens like General Electric, Xylem (XYL), Danaher, Honeywell International, Roper Technologies (ROP), and AMETEK (AME), and the other half selectively in the cyclical names that are better positioned today, such as Pentair, HD Supply Holdings (HDS),Actuant (ATU), Atkore International Group (ATKR), Ingersoll-Rand, and Eaton (ETN). We still believe risk-reward is mostly balanced and that the macro will remain choppy into 2017, supporting a positioning in the defensive names. But if investor sentiment improves on not-worse news and earnings results, the more cyclical names could fare better.

Top 10 Bank Stocks To Invest In Right Now: Insmed, Inc.(INSM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Insmed Incorporated (NASDAQ: INSM) shares shot up 113 percent to $26.15 following the announcement of positive top-line results from its Phase 3 Convert study of ALIS in adult patients with treatment-refractory nontuberculous Mycobacterial (NTM) lung disease..

Top 10 Bank Stocks To Invest In Right Now: Omnicom Group Inc.(OMC)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    We reprise five of last year’s components: Boeing (BA), CVS Health (CVS), International Business Machines (IBM), Omnicom Group (OMC) and Texas Instruments (TXN), which means they obviously are buys.

3 Top Penny Stocks to Watch in 2018

Investors searching for the top penny stocks to watch in 2018will want to take a close look at the three stocks we have on our list today, one of which is the top-performing penny stock of the year, with shares up 513.87% year to date.

But while penny stocks can bring triple-digit returns in a matter of weeks, they are also speculative investments that can see big pullbacks after making large gains.

For instance, VistaGen Therapeutics Inc. (Nasdaq: VTGN) shot up from $0.92 to $2.55 on Dec. 6. Since then, the stock pulled back to $1.02. Investors who bought at $2.55 are sitting on a 60% loss today (Dec. 18).

Now that you know the risks and potential rewards, here are three of thetop penny stocksso far this year.

But for investors looking for a stock with future potential, we’ll also show you our pick for the best small-cap stock to own right now…

top penny stocks to watch in 2018moneymorning.com/wp-content/blogs.dir/1/files/2017/12/shutterstock_382043125-75×50.jpg 75w” sizes=”(max-width: 300px) 100vw, 300px” title=”top penny stocks to watch in 2018″ />Top Penny Stocks to Watch in 2018, No. 3: Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc.(Nasdaq: PIRS) is our other top-performing penny stockfor 2017.

This pharmaceutical company’s share price has skyrocketed 219.68% so far in 2017. PIRS shares are up 68.82% since May 1, which is when the company announced that it was entering a collaboration agreement with AstraZeneca Plc. (NYSE: AZN).

The new partnership is developing a treatment for respiratory disease. According to the agreement’s terms, PIRS will receive $45 million upfront and will work on an asthma treatment called PRS-060. Once that treatment goes into a phase 1 trial for asthma, PIRS will receive another $12.5 million payment from AstraZeneca.

Provided the treatments are successful, there is an additional $2.1 billion available for future milestones and royalties.

Shares of PIRS are currently trading at $6.01.

URGENT: The Night Trader Is Up to 908% Total Gains

Top Penny Stocks to Watch in 2018, No. 2: AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals Inc.(Nasdaq: AVEO) is another top performer to put on yourpenny stocks to watchlist.

The company’s share price has soared 468.5% so far this year, with 321.8% of those gains accumulating since June 23. On that date, AVEO received approval in Europe for its cancer drug called Tivozanib.

Tivozanib is a drug that treats advanced renal cell carcinoma, which is the fastest-growing type of kidney cancer. The drug failed to receive FDA approval in 2013, but it was recommended for European approval this summer. The drug’s phase 3 trial results are expected in Q1 2018.

AVEO is currently trading at $2.90 per share.

Top Penny Stocks to Watch in 2018, No. 1: Marinus Pharmaceuticals Inc.

The performance ofMarinus Pharmaceuticals Inc.(Nasdaq: MRNS) in 2017 is testament that you can certainly make money with penny stocks.

On June 30, MRNS shares traded for $1.37; today, they trade at $8.41, for a gain of 513.87% over little more than five months.

In fact, this pharmaceutical company’s share price is up 205.45% since Aug. 21 alone, which is the date that it announced successful clinical trials of its epilepsy treatment, Ganaxolone. The new drug treats the CDKL5 disorder, which is a rare, severe genetic form of epilepsy that results in early onset seizures and disabling behavioral issues.

In addition to CDLK5 disorder, MRNS plans to develop a treatment for patients suffering from Lennox-Gastaut syndrome (LGS), another severe form of epilepsy.

Shares of MRNS are currently trading at $8.41.

VideoMeet the Trading Expert Who Could Help Make You a Millionaire

Even though these biotech penny stocks have returned some explosive gains to their investors, we aren’t recommending them as stocks to buy now, since their gains are in the rearview mirror.

The true money to be earned lies in finding a stock that is poised for growth in a strong or resilient market. This is where Money MorningSmall-Cap Specialist Sid Riggs comes in.

Sid picked a company called Neurocrine Biosciences Inc. (Nasdaq: NBIX) in December 2013, while it was trading at a share price of $9. Since then, it has exploded to $74.43, for a 727% gain.

Sid’s pick today is also a medical company that has bested earnings estimates by an average of 40.5% since Q4 2016.

This company was the first to create an at-home HIV test kit. This gives it a competitive edge in the testing sector, which is forecast for 56.7% growth, from $2.17 billion in 2016 to $3.4 billion, within the next three years.

Here is Sid’s pick for the best medical small-cap stock to own in the coming year…

The Best Medical Small-Cap Stock to Own Now

Join the conversation. Click here to jump to comments…

trading penny stocks

An Arizona-based company just offered to equip every police officer in the United States with a body camera for one year.

Axon (TASR) — formerly known as Taser International — said Wednesday that it will also provide police departments with all the hardware, data storage and training they need to use the devices.

At the end of one year, police departments can choose to purchase the devices and docking stations, which cost $400 and $200, respectively, or return them to Axon. If they keep the devices, they’ll also pay roughly $80 a month per camera for data storage.

All that will be free for the first year. And Axon founder and CEO Rick Smith said he expects the the body cameras will make it easier for officers to do their jobs, and will “drive important social change.”

“[The cameras] hold the potential to change police work as we know it, by seamlessly collecting an impartial record and reducing the need for endless paperwork. That’s why we’re giving this opportunity to every single police officer in America,” Smith said.

trading penny stocks: Palo Alto Networks, Inc.(PANW)

Advisors’ Opinion:

  • [By Paul Ausick]

    Palo Alto Networks Inc. (NYSE: PANW) reported fiscal second quarter 2017 adjusted diluted earnings per share (EPS) of $0.63 on revenue of $422.6 million. In the same period a year ago, the network security company reported EPS of $0.43 on revenue of $334.7 million. Second-quarter results compare to consensus estimates for EPS of $0.62 and $429.72 million in revenue.

  • [By Jayson Derrick]

    It is unclear which company or companies will benefit from this executive order. But that isn’t stopping investors from placing their bets as most cybersecurity stocks were trading higher during Friday’s trading session; at the same time, the Dow Jones Industrial Average and S&P 500 index were trading in the red.

    Shares of Barracuda Networks Inc (NYSE: CUDA) were trading higher by 2.98 percent at $21.77. Shares of Check Point Software Technologies Ltd. (NASDAQ: CHKP) were trading higher by 1.21 percent at $107.00. Shares of FireEye Inc (NASDAQ: FEYE) were trading higher by 0.70 percent at $14.55. Shares of Palo Alto Networks Inc (NYSE: PANW) were trading higher by 0.62 percent at $115.86.

    Related Links:

  • [By Peter Graham]

    A long term performance chart shows Barracuda Networks peaking in 2015 before drifting into underperformance and then back up againwhile mid cap Fortinet Inc (NASDAQ: FTNT) and large cap Palo Alto Networks Inc (NYSE: PANW) also peaked in 2015 and bounced back a bit last year:

trading penny stocks: Inogen, Inc(INGN)

Advisors’ Opinion:

  • [By Michael A. Robinson]

    I put these rules in action for you in March 2015 when I recommendedInogen Inc.(Nasdaq: INGN)here in these pages.

    Inogen is pioneering the use of portable oxygen concentrators (POCs). And theGoleta, Calif.-based firm boasts breakthrough technology that has disrupted its entire sector.

trading penny stocks: VistaGen Therapeutics, Inc. (VTGN)

Advisors’ Opinion:

  • [By Money Morning News Team]

    For instance, VistaGen Therapeutics Inc. (Nasdaq: VTGN) shot up from $0.92 to $2.55 on Dec. 6. Since then, the stock pulled back to $1.02. Investors who bought at $2.55 are sitting on a 60% loss today (Dec. 18).

  • [By SEEKINGALPHA.COM]

    Four ideas turned up in this screen that might be of interest (prices as of February 9th close):

    Heron Therapeutics (NASDAQ:HRTX) by ONeil Trader – published February 3rd, 2017, $525M Market cap, down ~2% since publication, author’s price target offers 130% upside. HRTX isn’t a generic drug provider, but its CINV franchise vs. the growth of a new drug gives it a similar sort of profile, and arguably a favorable risk/reward; commenters were mostly positive on the thesis. VistaGen Therapeutics (OTC:VTGN) by Logical Assessment – published July 29, 2016, $24M market cap, down 16% since publication, author’s price target offers 100%+ upside. This is obviously deeper into the speculative pile, but if the author’s thesis holds about VistaGen’s unique angle in the antidepressant drug space, comparable deals suggest good upside. (Of course, it’s always dangerous to rely solely on comparables). Dr. Reddy’s Laboratories (NYSE:RDY) by Buddy Lyons – published July 5, 2016, $7.6B market cap, down ~13% since publication, author’s price target offers just shy of 100% upside. Dr. Reddy’s is a more obvious comparable to TEVA, with a generics business but also a manufacturing business and a proprietary products branch. The company bought a divestiture package of drugs from TEVA as part of the Allergan/Actavis deal. A big overhang was an FDA warning letter; the FDA is due to reinspect facilities this month or next, which could resolve that one way or another. Lannett (NYSEMKT:LCI) by Lateral Capital Management – published May 27, 2016, $750M market cap, down ~9% since publication, author’s price target offers 75% upside. LCI’s trading had been 90% correlated with Valeant, but Lateral Capital Management argues that the correlation is unjustified. The article does a deep dive into the company’s valuation and credit risk, and was well received at the time, even if the market hasn’t agreed…yet.

    I also checked to see if there are any ideas starting to play out on the short si

  • [By William Romov]

    VistaGen Therapeutics Inc. (Nasdaq: VTGN) is among the top penny stocks to watch this week after climbing 135% in just three trading sessions last week.

trading penny stocks: World Energy Solutions Inc(DE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    In my Trader column on Dec.3, I argued for more upside in Deere (DE), despite the fact that it had gained more than 30% on the year. Part of the argument was technical–Deere had finally broken out of a trading range that had been in place for five years–but I also noted that the agricultural equipment maker had been able to grow earnings despite continued sluggish demand for farm equipment. Today, Baird’s Mircea Dobre and Joseph Grabowski make a similar argument as they name Deere an Idea for 2017:

    Getty Images

    Deere has upside even after a strong 4Q16 where the real surprise was strong Ag margin rather than confirmation that a turn in the Ag cycle is imminent. This is where the opportunity lies: as investors find additional evidence supporting a 2017 North American ag bottom the multiple can continue expanding towards the historical peak of 25x baked in our target. For perspective, Caterpillar (CAT) is trading >30x on the premise of a bottom in several cyclical end markets (mining, infrastructure, oil & gas).

    Shares of Deere have ticked up 0.1% to $103.49 at 1:29 p.m. today, while Caterpillar has advanced 0.1% to $93.28. The Industrial Select Sector SPDR ETF (XLI) is up 0.1% at $62.50.

  • [By Chris Lange]

    And Deere & Co. (NYSE: DE) will share its most recent quarterly numbers on Wednesday. The consensus estimates call for $1.45 in EPS and $6.99 billion in revenue. Shares were last seen trading at $135.77, in a 52-week range of $91.33 to $136.69. The consensus price target is $132.37.

  • [By JJ Kinahan]

    Earnings season is slowing down, but there’s still a few companies left to report. On Friday, we’ll get a look at the state of agriculture with Deere & Company (NYSE: DE).  And if you have time, make sure to check out today’s market update to see what else is happening.

  • [By Lisa Levin]

    Deere & Company (NYSE: DE) reported better-than-expected results for its fourth quarter on Wednesday.

    Deere reported Q4 earnings of $1.57 per share on revenue of $8.018 billion. However, analysts were expecting a profit of $1.47 per share on sales of $7.05 billion.

  • [By Casey Wilson]

    Since farming is such an equipment-intense activity, investors can profit by making investments in the agricultural equipment manufacturers, like Deere & Co. (NYSE: DE), the company behind the iconic John Deere brand.

  • [By SEEKINGALPHA.COM]

    Sometimes companies can change their stripes. That may the case for Deere (DE).

    The company had faced a weak market due to declining agriculture sales and a strong dollar. “It was difficult to get enthusiastic about Deere,” Cramer said.

trading penny stocks: Tandy Leather Factory, Inc.(TLF)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Armour Residential REIT Inc. (NYSE: ARR), Ducommun Inc. (NYSE: DCO), PJT Partners Inc. (NYSE; PJT), Sonic Automotive Inc. (NYSE: SAH)and Tandy Leather Factory Inc. (NASDAQ: TLF).

stock information

In January, my True Wealth Systems computers alerted me to the big story the rest of the world was missing…   They told me a stealth bull market was beginning in Europe.   You see, European stocks are staging a major breakout this year. And that's why the computers behind my high-priced True Wealth Systems service are signaling now is the time to buy.   But I've got an even more important reason to own Europe today… one that could mean triple-digit gains if history is any guide.   Let me explain…   Let's think about two different investments… We'll call them Investment A and Investment B.   A and B are similar… but not identical. They generally move up and down together… But they don't track each other perfectly.   You can think about it in terms of the housing market. For example, if your neighbor's house goes up in value, then chances are yours will go up, too.

stock information: Immunomedics, Inc.(IMMU)

Advisors’ Opinion:

  • [By Chris Lange]

    Immunomedics, Inc. (NASDAQ: IMMU) saw its shares rise after the firm sent out a letter to shareholders imploring them to vote for its director nominees at the upcoming annual stockholders meeting on February 16. The board of directors is making this request because it is currently waging a proxy contest with venBio SelectAdvisor.

stock information: VistaGen Therapeutics, Inc. (VTGN)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Four ideas turned up in this screen that might be of interest (prices as of February 9th close):

    Heron Therapeutics (NASDAQ:HRTX) by ONeil Trader – published February 3rd, 2017, $525M Market cap, down ~2% since publication, author’s price target offers 130% upside. HRTX isn’t a generic drug provider, but its CINV franchise vs. the growth of a new drug gives it a similar sort of profile, and arguably a favorable risk/reward; commenters were mostly positive on the thesis. VistaGen Therapeutics (OTC:VTGN) by Logical Assessment – published July 29, 2016, $24M market cap, down 16% since publication, author’s price target offers 100%+ upside. This is obviously deeper into the speculative pile, but if the author’s thesis holds about VistaGen’s unique angle in the antidepressant drug space, comparable deals suggest good upside. (Of course, it’s always dangerous to rely solely on comparables). Dr. Reddy’s Laboratories (NYSE:RDY) by Buddy Lyons – published July 5, 2016, $7.6B market cap, down ~13% since publication, author’s price target offers just shy of 100% upside. Dr. Reddy’s is a more obvious comparable to TEVA, with a generics business but also a manufacturing business and a proprietary products branch. The company bought a divestiture package of drugs from TEVA as part of the Allergan/Actavis deal. A big overhang was an FDA warning letter; the FDA is due to reinspect facilities this month or next, which could resolve that one way or another. Lannett (NYSEMKT:LCI) by Lateral Capital Management – published May 27, 2016, $750M market cap, down ~9% since publication, author’s price target offers 75% upside. LCI’s trading had been 90% correlated with Valeant, but Lateral Capital Management argues that the correlation is unjustified. The article does a deep dive into the company’s valuation and credit risk, and was well received at the time, even if the market hasn’t agreed…yet.

    I also checked to see if there are any ideas starting to play out on the short si

stock information: Energy XXI Ltd.(EXXI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Energy XXI Ltd (NASDAQ: EXXI) were down 72 percent to $0.181 after the company announced that it and some of its subsidiaries have entered into a Restructuring Support Agreement (RSA) with holders of more than 63 percent of its secured second lien 11.0 percent notes. Energy XXI added that in order to implement the terms of the RSA, it has commenced cases under Chapter 11 of the Bankruptcy Code.

stock information: AFC Enterprises Inc.(AFCE)

Advisors’ Opinion:

  • [By AnnaLisa Kraft]

    AFC Enterprises (NASDAQ: AFCE  ) , which owns the Popeye’s Louisiana Kitchen quick- serve chain, once an undiscovered gem, has now soared 66% over the last year.

technical trading

In a short period of time readers and I have been pleasantly surprised by the outperformance of this model portfolio.

Click to enlarge Figure 1: Ceviche Fund Snapshot November 19th

While the fund takes a “go anywhere” approach, lately the opportunities we’ve been seeing are in biotech companies that are undervalued relative to their future prospects, with catalysts on the way that could result in near to medium term share price appreciation.

In hindsight, it wasn’t great timing when I started the fund near the beginning of correction in biotech. However, when it comes to the markets in general I don’t try to predict future movement- instead I look for price action, money flow, and the fundamental story on individual stocks I take positions in.

technical trading: Forward Pharma A/S(FWP)

Advisors’ Opinion:

  • [By George Budwell]

    Shares of theDanish drugmaker Forward Pharma A/S (NASDAQ:FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ:BIIB)involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork overa non-refundable$1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera’snet sales to Forward starting in 2021.

  • [By Jim Robertson]

    Last Friday, our Under the Radar Moversnewsletter suggested going long on small cap clinical-stage biopharmaceutical stock Forward Pharma A/S (NASDAQ: FWP):

technical trading: Sohu.com Inc.(SOHU)

Advisors’ Opinion:

  • [By R. Chandrasekaran]

    The following stocks are rated Underweight:

    Baidu. Sohu.com Inc (NASDAQ: SOHU).

    Full ratings data available on Benzinga Pro.

    Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

  • [By Matthew Smith]

    Shares in Sohu.com (SOHU) continued their rapid rise, hitting yet another fresh 52-week high during the session, as the company announced the special dividend from Sohou yesterday (press release located here). Sohu.com will receive nearly $161.2 million in the transaction which is part of the overall $400 million deal with Tencent (TCEHY.PK) which was announced not too long ago. These are exciting times in the internet space as we move from computers to mobile devices, but China’s internet landscape looks like the ‘Wild West’ right now and we expect to see further deals as companies jockey for position in their respective niches and consolidation begins as the larger players look to step up growth and gain exposure to new business segments.

  • [By Belinda Cao]

    Sohu.com Inc. (SOHU), which sold a stake in its search unit to Tencent Holdings Ltd. (700), advanced 11 percent for the week to $72.06. It retreated 5.9 percent Sept. 20. Tencent, Chinas biggest Internet company by market value, paid $448 million for a 36.5 percent stake in Sohus Sogou unit last week and merge its own search service with Sogou.

technical trading: athenahealth, Inc.(ATHN)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Meanwhile, earnings season continued to play out, and although the technology industry saw some extremely encouraging reports, not all stocks participated in the rally. Athenahealth (NASDAQ:ATHN), Synchrony Financial (NYSE:SYF), and Time (NYSE:TIME) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By WWW.THESTREET.COM]

    Shares of Athena Health (ATHN) are up 37% in just over a month. Is there still more room to run?

    Cramer said for years Athena had been a fast-growing stock, but as the company transitioned from growth to profitability, things began to get ugly. The company’s bombastic CEO, and his “colorful” personality began to rub shareholders the wrong way.

  • [By Ben Levisohn]

    Athenahealth (ATHN) last night announced that its CFO and administrative chief, Kristi Matus, would be leaving the company. Her departure has not been embraced by investors, who have pushed shares lower today. Leerink’s David Larsen understands their concerns:

    In our view, the CFO departure may be indicative of internal operational challenges. We still think it is possible that Kristi Matus is seeking an environment that is not as demanding as ATHN, though this has not been confirmed by management. Management harped on the point that bifurcation is part of the strategic initiative of ATHN to reenergize the culture of the company, and Jonathan Bush noted how he himself hopes to spend more time on talent and culture and less time on entering new markets and building new products.

    We continue to believe that ATHN is facing challenges. We continue to believe the market is fundamentally slowing and bookings growth may become more lumpy as we progress through 2016. We still believe there will be a slow-down in the bookings growth rate b/c of a possible slow-down in the ambulatory EMR market and the fact that we are in the final payment year of Meaningful Use. Much of the call focused on Kristi Matus’s departure as a major loss for the company of a leader who was “masterful with investors.” According to management, the decision to split the CFO and CFAO responsibilities was not a reflection of her ability.

    Baird’s Matthew Gillmor and Sean McBride are less worried:

    The unexpected resignation of CFO Kristi Matus is disappointing, but the reasons for her departure seem somewhat understandable, in our view (potentially viewed bifurcation of CFO/CAO role as a demotion). We think incoming CFO Karl Stubelis is very strong and should provide helpful continuity, both internally and externally (currently serves as Controller and previously as acting CFO). Finally, the CFO change does not change our positive long-term thesi

technical trading: First Horizon National Corporation(FHN)

Advisors’ Opinion:

  • [By Lisa Levin] Related WFC Why Bank ETFs Fell On Friday Despite Decent Earnings Phil's Stock World: Funtime Friday Earnings Season Starts Today Rising Book Values and Margins of Safety (GuruFocus)
    Related C Earnings Preview: Financial Giants BAC, GS, And MS Report Q2 Results This Week Why Bank ETFs Fell On Friday Despite Decent Earnings Palo Capital, Inc. Buys Citigroup Inc, Schlumberger, NetApp Inc, Sells Citrix Systems Inc, … (GuruFocus) Companies Reporting Before The Bell
    Wells Fargo & Co (NYSE: WFC) is estimated to report quarterly earnings at $1.02 per share on revenue of $22.51 billion.
    Citigroup Inc (NYSE: C) is projected to report quarterly earnings at $1.26 per share on revenue of $17.71 billion.
    JPMorgan Chase & Co. (NYSE: JPM) is expected to report quarterly earnings at $1.65 per share on revenue of $25.61 billion.
    PNC Financial Services Group Inc (NYSE: PNC) is projected to report quarterly earnings at $2.02 per share on revenue of $4.00 billion.
    First Republic Bank (NYSE: FRC) is estimated to report quarterly earnings at $1.1 per share on revenue of $675.70 million.
    First Horizon National Corp (NYSE: FHN) is projected to report quarterly earnings at $0.28 per share on revenue of $337.89 million.

     

technical trading: VistaGen Therapeutics, Inc. (VTGN)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Four ideas turned up in this screen that might be of interest (prices as of February 9th close):

    Heron Therapeutics (NASDAQ:HRTX) by ONeil Trader – published February 3rd, 2017, $525M Market cap, down ~2% since publication, author’s price target offers 130% upside. HRTX isn’t a generic drug provider, but its CINV franchise vs. the growth of a new drug gives it a similar sort of profile, and arguably a favorable risk/reward; commenters were mostly positive on the thesis. VistaGen Therapeutics (OTC:VTGN) by Logical Assessment – published July 29, 2016, $24M market cap, down 16% since publication, author’s price target offers 100%+ upside. This is obviously deeper into the speculative pile, but if the author’s thesis holds about VistaGen’s unique angle in the antidepressant drug space, comparable deals suggest good upside. (Of course, it’s always dangerous to rely solely on comparables). Dr. Reddy’s Laboratories (NYSE:RDY) by Buddy Lyons – published July 5, 2016, $7.6B market cap, down ~13% since publication, author’s price target offers just shy of 100% upside. Dr. Reddy’s is a more obvious comparable to TEVA, with a generics business but also a manufacturing business and a proprietary products branch. The company bought a divestiture package of drugs from TEVA as part of the Allergan/Actavis deal. A big overhang was an FDA warning letter; the FDA is due to reinspect facilities this month or next, which could resolve that one way or another. Lannett (NYSEMKT:LCI) by Lateral Capital Management – published May 27, 2016, $750M market cap, down ~9% since publication, author’s price target offers 75% upside. LCI’s trading had been 90% correlated with Valeant, but Lateral Capital Management argues that the correlation is unjustified. The article does a deep dive into the company’s valuation and credit risk, and was well received at the time, even if the market hasn’t agreed…yet.

    I also checked to see if there are any ideas starting to play out on the short si

technical trading: CVS Health Corporation(CVS)

Advisors’ Opinion:

  • [By JACK HOUGH]

    CVS Health (CVS) is a long-term winner, returning more than 14% a year over the past decade, double the yearly return of the S&P 500. It has sold off from over $110 this past summer to a recent $93, presenting a buying opportunity. The decline stems in part from management last quarter issuing 2016 earnings guidance below Wall Street expectations. Even so, it implies earnings per share growth of 10% to 14% next year. Shares now sell for 16 times projected earnings for the next four quarters, down from close to 20 times earlier this year.

    The company remains at the center of trends that could keep earnings growing at a double-digit pace through the end of the decade. Increased medical-plan coverage is driving more prescriptions. So is the aging of the baby boomers. Medical plans are looking to save on drugs, and some are turning over more business to drug-plan managers like CVS’ Caremark. Patients looking for savings, including those who remain uninsured, can take care of basic health-care needs through walk-in clinics, like CVS’ Minute Clinic chain. The stock’s dividend yield is unremarkable at 1.5%, but payments are expected to grow more than 60% cumulatively over the next three years. 
  • [By Peter Graham]

    A long term performance chart shows shares of Rite Aid Corporation outperforming thealso solid performanceoflarge capsWalgreens Boots AllianceandCVS Caremark Corporation (NYSE: CVS):

  • [By Casey Wilson]

    Investors are already seeing the writing on the wall. Shares of potential rivals in the retail pharmacy space were spooked by the news on Wednesday (May 18). Both CVS Health Corp. (NYSE: CVS) and Walgreens Boots Alliance Inc. (Nasdaq: WBA) were down more than 3% in afternoon trading. At the same time, Amazon was up 1.48% on Wednesday and is currently trading up 0.84%.

buy penny stocks

Toward the end of trading Wednesday, the Dow traded up 0.74 percent to 20,842.08 while the NASDAQ rose 0.56 percent to 5,931.37. The S&P also rose, gaining 0.66 percent to 2,375.73.

Leading and Lagging Sectors

Wednesday afternoon, the industrial sector proved to be a source of strength for the market. Leading the sector was strength from Plug Power Inc (NASDAQ: PLUG) and Envirostar Inc (NYSE: EVI).

In trading on Wednesday, telecommunications services shares rose by just 0.03 percent. Meanwhile, top losers in the sector included Internet Initiative Japan Inc. (ADR) (NASDAQ: IIJI), down 4 percent, and DigitalGlobe Inc (NYSE: DGI), down 2 percent.

Top Headline

Walgreens Boots Alliance Inc (NASDAQ: WBA) reported in-line earnings for its second quarter, while sales missed estimates. Walgreens also announced a $1 billion buyback plan.

Walgreens reported Q2 adjusted earnings of $1.36 per share on revenue of $29.4 billion. Analysts expected earnings of $1.36 per share on revenue of $30.24 billion. The company also expects to close around 60 more stores.

buy penny stocks: 3D Systems Corporation(DDD)

Advisors’ Opinion:

  • [By Beth McKenna]

    Stratasys’ stock, which took a beating from 2014 through last year, is having a great 2017. It’s gained 81.1% through May 12, crushing the S&P 500’s 7.6% total return and outpacing prime rival 3D Systems'(NYSE:DDD) powerful 64% gain.

  • [By Peter Graham]

    The Q4 2016 earnings report for small cap 3D printing stock3D Systems Corporation (NYSE: DDD) is scheduled for before the market opens onTuesday (February 28th). It goes without saying that 3D printing / 3D printer stocks did not live up to the lofty expectations of investors. In the case of 3D Systems Corporation,anew CEO came onboard last April with him conducting a comprehensive review of the Companys operations while Q3 earnings werebetter-than-expected.

  • [By Peter Graham]

    A long term performance chart shows shares of Stratasys, Ltd along with other small cap 3D printing stocks like 3D Systems Corporation (NYSE: DDD), ExOne Co (NASDAQ: XONE)and Voxeljet AG (NYSE: VJET) all peaking a few years with the bubble bursting and all showing some signs of stabilization or even a bit of a recent uptick:

  • [By Peter Graham]

    Small cap 3D printing stock3D Systems Corporation (NYSE: DDD) reported Q2 2017 earnings after the market closed on Wednesday with results missing expectations. Revenue grew 1% to $159.5 million as demand from healthcare and industrial customers as well as strength in EMEA was offset by softer sales in APAC and lower revenue from professional printers. The net loss was $8.4 million versus anet loss of $4.6 million. The CEO commented:

  • [By Beth McKenna]

    While Stratasys’ stock is still down significantly from its all-time high, it’s showing signs of life this year. It’s gained 17% in 2017, through March 3, outpacing rival 3D Systems’ (NYSE:DDD)9.3% gain and the S&P 500’s total return of 6.9%. Shares of 3D Systems had been riding higher in 2017, through plummeted 10% after the company announced earnings on Feb. 28. Quarterly revenue and 2017 revenue guidance came in lighter than Wall Street analysts were expecting.

  • [By Peter Graham]

    A long term performance chart shows Voxeljet AGalong with other small cap 3D printing stocks like ExOne Co (NASDAQ: XONE), 3D Systems Corporation (NYSE: DDD) and Stratasys, Ltd (NASDAQ: SSYS) all peaking around 2013-2014, but also showing some signs of life in recent months:

buy penny stocks: Prism Technologies Group, Inc.(PRZM)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of TOWERVIEW LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=TOWERVIEW+LLC

    These are the top 5 holdings of TOWERVIEW LLCTejon Ranch Co (TRC) – 2,795,000 shares, 28.55% of the total portfolio. Saga Communications Inc (SGA) – 1,196,723 shares, 28.51% of the total portfolio. Shares reduced by 1.22%Barnes & Noble Inc (BKS) – 2,375,000 shares, 10.25% of the total portfolio. Corning Inc (GLW) – 600,000 shares, 7.56% of the total portfolio. Barnes & Noble Education Inc

  • [By WWW.GURUFOCUS.COM]

    For the details of TOWERVIEW LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=TOWERVIEW+LLC

    These are the top 5 holdings of TOWERVIEW LLCTejon Ranch Co (TRC) – 2,795,000 shares, 28.55% of the total portfolio. Saga Communications Inc (SGA) – 1,196,723 shares, 28.51% of the total portfolio. Shares reduced by 1.22%Barnes & Noble Inc (BKS) – 2,375,000 shares, 10.25% of the total portfolio. Corning Inc (GLW) – 600,000 shares, 7.56% of the total portfolio. Barnes & Noble Education Inc

buy penny stocks: VistaGen Therapeutics, Inc. (VTGN)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Four ideas turned up in this screen that might be of interest (prices as of February 9th close):

    Heron Therapeutics (NASDAQ:HRTX) by ONeil Trader – published February 3rd, 2017, $525M Market cap, down ~2% since publication, author’s price target offers 130% upside. HRTX isn’t a generic drug provider, but its CINV franchise vs. the growth of a new drug gives it a similar sort of profile, and arguably a favorable risk/reward; commenters were mostly positive on the thesis. VistaGen Therapeutics (OTC:VTGN) by Logical Assessment – published July 29, 2016, $24M market cap, down 16% since publication, author’s price target offers 100%+ upside. This is obviously deeper into the speculative pile, but if the author’s thesis holds about VistaGen’s unique angle in the antidepressant drug space, comparable deals suggest good upside. (Of course, it’s always dangerous to rely solely on comparables). Dr. Reddy’s Laboratories (NYSE:RDY) by Buddy Lyons – published July 5, 2016, $7.6B market cap, down ~13% since publication, author’s price target offers just shy of 100% upside. Dr. Reddy’s is a more obvious comparable to TEVA, with a generics business but also a manufacturing business and a proprietary products branch. The company bought a divestiture package of drugs from TEVA as part of the Allergan/Actavis deal. A big overhang was an FDA warning letter; the FDA is due to reinspect facilities this month or next, which could resolve that one way or another. Lannett (NYSEMKT:LCI) by Lateral Capital Management – published May 27, 2016, $750M market cap, down ~9% since publication, author’s price target offers 75% upside. LCI’s trading had been 90% correlated with Valeant, but Lateral Capital Management argues that the correlation is unjustified. The article does a deep dive into the company’s valuation and credit risk, and was well received at the time, even if the market hasn’t agreed…yet.

    I also checked to see if there are any ideas starting to play out on the short si

buy penny stocks: WGL Holdings Inc(WGL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Brean Capital reported on Friday that it has upgraded natural gas utility company WGL Holdings Inc (WGL).

    The firm has raised its rating on WGL from “Hold” to “Buy,” and has given the company a $46 price target. This price target suggests a 12% increase from the stock’s current price of $40.62. The upgrade was primarily based on valuation and future investment opportunities.

    “Like many utilities in the gas LDC space, the shares of WGL Holdings have come off recent highs and are now trading at a level we consider attractive,” analyst Michael Gaugler comments. “Beyond valuation, we consider the recent announcement of conditional approval of Dominion’s Cove Point facility for LNG export as a positive development in terms of future investment opportunities, given the company’s one-third interest in the Commonwealth Pipeline project, which we believe will be revisited due to future increased demand.”

    WGL Holdings shares were mostly flat during pre-market trading Friday. The stock has been mostly flat YTD.

buy penny stocks: Deckers Outdoor Corporation(DECK)

Advisors’ Opinion:

  • [By Matt Hogan]

    SKX is also highly attractive in a relative basis when compared to several of its publicly traded peers: Foot Locker, Inc. (NYSE: FL), Deckers Outdoor Group (NYSE: DECK), Wolverine World Wide, Inc. (NYSE: WWW) and Columbia Sportswear Company (NASDAQ: COLM). The company's forward EBITDA multiple of 6.9x is equal or below all of the comparable companies: FL (6.9x), DECK (7.6x), WWW (10.1x) and COLM (10.8x).

  • [By Ben Levisohn]

    Hanesbrands was just one of many retail companies that got shellacked this week. Under Armour (UAA) tumbled 29% after missing earnings forecasts and cutting its guidance, while Deckers Outdoor (DECK) plunged 21% after its earnings missed the Street consensus, and Ralph Lauren (RL) plummeted 13% after its CEO stepped down.

buy penny stocks: Regions Financial Corporation(RF)

Advisors’ Opinion:

  • [By Sean Williams]

    Income investors often turn to bank stocks when looking for a steady dividend, but few offer the dividend growth potential of Southeastern regional bankRegions Financial (NYSE:RF).

  • [By Jon C. Ogg]

    In the super-regional banks that are not money center banks, Regions Financial Corp. (NYSE: RF) was up 6.3% at $13.22, and Zions Bancorporation (NASDAQ: ZION) was last seen up 3.8% at $38.30. They would both do better with lower regulatory costs and be able to better compete against larger banks when their stress test results had not been as strong.